Microcap Ledger

Tickers · $NXGL

Nexgel, Inc. $NXGL

By Microcap Ledger desk · CIK 0001468929

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Capital Market
Sector
Surgical & Medical Instruments & Apparatus
Headquarters
Langhorne, PA
Fiscal year end
December 31
Shares outstanding
9,747,663 [10-Q 2026-08-17]
as of 2026-08-14

Sources: [10-K 2026-03-31]

What the company doesAI summary of filing

NexGel manufactures high water content, electron beam cross-linked hydrogel products used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company operates as a contract manufacturer supplying gels to third parties who incorporate them into their own products, and also sells branded consumer products directly to consumers under brands including Medagel, Kenkoderm, and Silly George. The company generates revenue from contract manufacturing, consumer product sales, and white label opportunities, and is developing medical devices including NEXDrape and NEXDerm that it intends to license rather than commercialize directly. [10-K 2026-03-31]

Segments: Contract Manufacturing, Consumer Products, Custom and White Label, Medical Devices

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
6 months to Jun 2026$6.34M−$4.56M −$2.70M$1.71M[10-Q 2026-08-17]
FY ended Dec 2025$11.42M−$3.00M −$1.31M$317.0K[10-K 2026-03-31]
FY ended Dec 2024$8.69M−$3.28M −$3.87M$1.81M[10-K 2026-03-31]
Quarterly cash burn
−$1.35M
Cash runway Estimate
~3.8 months

Estimate: cash at the end of the period (6 months to Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2025-03-277,654,037[10-K 2025-03-27]
2025-05-137,654,537[10-Q 2025-05-13]
2025-08-128,067,580[10-Q 2025-08-12]
2025-11-128,143,133[10-Q 2025-11-12]
2026-03-318,475,693[10-K 2026-03-31]
2026-04-288,849,665[10-K/A 2026-04-30]
2026-05-139,131,055[10-Q 2026-05-14]
2026-08-149,747,663[10-Q 2026-08-17]
Shelf registration
S-1 filed 2026-08-20; no effectiveness notice found in EDGAR [S-1 2026-08-20]

Listing status

Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-04-24. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

DateEventDetailsDeadlineFiling
2026-04-248-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2026-04-24]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-06-23Levy Adam R.sell5,000$0.59[4 2026-06-23]
2026-06-18Levy Adam R.sell6,000$0.59[4 2026-06-23]
2026-06-11Levy Adam R.sell3,000$0.61[4 2026-06-15]
2026-06-08Levy Adam R.sell3,000$0.55[4 2026-06-09]
2026-06-04Levy Adam R.sell3,000$0.59[4 2026-06-09]
2026-06-01Levy Adam R.sell2,000$0.59[4 2026-06-03]
2026-05-29Levy Adam R.sell3,000$0.60[4 2026-05-29]
2026-05-28Levy Adam R.sell7,000$0.61[4 2026-05-29]
2026-05-27Levy Adam R.sell3,000$0.60[4 2026-05-29]

Catalysts and calendar

Recent filings and releases
DateTypeTitle
2026-10-078-KChange to security holder rights; Charter, bylaws or fiscal year change
2026-09-248-KRegulation FD disclosure
2026-09-238-KShareholder vote results
2026-08-24DEF 14AProxy statement
2026-08-218-KDirector or officer change
2026-08-20S-1Registration statement
2026-08-178-KResults of operations
2026-08-1710-QQuarterly report
2026-08-17NT 10-QNotice of late quarterly report
2026-08-14PRE 14AProxy statement
2026-08-058-KShareholder vote results
2026-07-298-KDirector or officer change

Facts as of . Small caps move fast; check the latest filings.